Colon to Rectum

Gastrointest Endosc. 2023;97(4):780−9.e4

Zwager LW, Mueller J, Stritzke B, Montazeri NSM, Caca K, Dekker E, Fockens P, Schmidt A, Bastiaansen BAJ; Dutch eFTR Working Group and Ger-man collaborating centers

Adverse events of endoscopic full-thickness resection: Results from the German and Dutch nationwide colorectal FTRD registry


Background and aims: Endoscopic full-thickness resection (eFTR) is emerging as a minimally invasive alternative to surgery for complex colorectal lesions. Previous studies have demonstrated favorable safety results; however, large studies representing a generalizable estimation of adverse events (AEs) are lacking. Aim of the present study was to provide further insight in AEs after eFTR.
Methods: Data from all registered eFTR procedures in the German and Dutch colorectal full-thickness resection device registries between July 2015 and March 2021 were collected. Safety outcomes included immediate and late AEs.
Results: Of 1892 procedures, the overall AE rate was 11.3% (213/1892). No AE-related mortality occurred. Perforations occurred in 2.5% (47/1892) of all AEs, 57.4% (27/47) of immediate AEs, and 42.6% (20/47) of delayed AEs. Successful endoscopic closure was achieved in 29.8% of cases (13 immediate and 1 delayed), and antibiotic treatment was sufficient in 4.3% (2 delayed). The appendicitis rate for appendiceal lesions was 9.9% (13/131), and 46.2% (6/13) could be treated conservatively. The severe AE rate requiring surgery was 2.2% (42/1892), including de-layed perforations in 0.9% (17/1892) and immediate perforations in 0.7% (13/1892). Delayed perforations occurred between days 1 and 10 (median, 2) after eFTR, and 58.8% (10/17) were located on the left side. Other severe AEs were appendicitis (0.4%, 7/1892), luminal stenosis (0.1%, 2/1892), delayed bleeding (0.1%, 1/1892), pain after eFTR close to the dentate line (0.1%, 1/1892), and grasper entrapment in the clip (0.1%, 1/1892).

Conclusions: Colorectal endoscopic full-thickness resection (eFTR) is a safe procedure with a low risk for severe adverse events (AEs) in everyday practice and without AE-related mortality. These results further support the position of eFTR as an established minimally invasive technique for complex colorectal lesions.

Dr. B.A.J. Bastiaansen, Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Location AMC, Amsterdam, The Netherlands

DOI: 10.1016/j.gie.2022.11.005

Back to overview

this could be of interest:

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomized, double-blind, controlled, phase 2, proof-of-concept trial

Lancet Gastroenterol Hepatol. 2023;8(4):307–20

Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer

N Engl J Med. 2023;388(18):1657–67

More articles on the topic